FDA has granted priority review for Boehringer Ingelheim’s zongertinib NDA for treating unresectable or metastatic NSCLC.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite facing operating loss and margin pressures.

Davis New York Venture Fund returned +17.51% in 2024. The fund has consistently grown wealth for shareholders since its ...

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

His proposal could prevent pharmacy benefit managers from inflating medication costs by banning spread pricing.

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...